NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Prestige Consumer Healthcare Inc. (PBH) Stock Analysis

Prestige Consumer Healthcare Inc. (PBH) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

PBH

$52.26

−$0.30 (−0.57%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PBH with… →

PBH Key Statistics

As of Sep 4, 2026
Trading
Open
$51.80
Previous Close
$52.56
Day's Range
51.80–52.58
52-Week Range
42.62–71.07
Volume
342.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.33
Valuation
Market Cap
$2.48B
P/E Ratio
14.72
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
10.28
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.61
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.24
EPS (ttm)Profit attributable to each share over the last twelve months.
3.55
Financials (FY)
Revenue (FY)
$1.09B−4.31%
Net Income (FY)
$190.30M−11.32%
Profit marginThe share of revenue left as profit after all costs and taxes.
15.57%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
47.37M
1-Year Return
−21.71%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
582.87K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PBH Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−15.29%
2025−21.00%
2024+27.56%
2023−2.20%
2022+3.22%
2021+73.93%
2020−13.90%
2019+31.15%
2018−30.47%
2017−14.76%
2016 (partial year)+3.95%

As of September 4, 2026.

PBH Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$1.09B$190.30M17.5%
2024$1.14B$214.61M18.9%
2023$1.13B$209.34M18.6%
2022$1.13B−$82.31M−7.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.09B$595.58M$309.41M$190.30M17.5%
2024$1.14B$634.46M$349.24M$214.61M18.9%
2023$1.13B$624.45M$342.43M$209.34M18.6%
2022$1.13B$625.29M$347.80M−$82.31M−7.3%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

PBH Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricPBHDrug Manufacturers - Specialty & Generic medianvs median
P/E14.7219.2724% below
P/S ratio2.242.302% below
Profit margin15.57%−3.14%18.7 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Prestige Consumer Healthcare Inc. (PBH) at $2.48B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 890 employees.

The most recent close on file for PBH is $52.26, dated September 4, 2026. That is −$0.30 (−0.57%) against the previous close. Over the past 52 weeks the price has ranged from $42.62 to $71.07. The latest close sits 22.62% above that 52-week low.

Financial Health

In fiscal 2025, Prestige Consumer Healthcare Inc. reported revenue of $1.09B. That is −4.31% against the prior fiscal year, when revenue was $1.14B. Net income for the same year was $190.30M. That is −11.32% against the prior fiscal year. The reported profit margin is 15.57%. That is 18.7 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are 3.55.

Across the 4 fiscal years on file, revenue moves from $1.13B in 2022 to $1.09B in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 14.72 times earnings. That is 23.59% below the Drug Manufacturers - Specialty & Generic median of 19.27. The forward P/E on file is 10.28. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.61. Measured against sales, the shares trade at 2.24 times revenue. On price-to-sales that is 2.42% below the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Beta against the wider market is reported at 0.33. Annualized volatility over the trailing 10 years is 29.69%. The trailing one-year price return is −21.71%. Measured over 10 years, that is +0.86% a year compounded.

Growth & Income

No dividend is on file for PBH.

2026 is still running; the price is −15.29% year to date. The strongest complete calendar year on file is 2021 at +73.93%; the weakest is 2018 at −30.47%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Prestige Consumer Healthcare Inc. (PBH) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Prestige Consumer Healthcare Inc. PBH $2.48B 14.7
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Prestige Consumer Healthcare Inc. trades at a P/E of 14.7.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Visit website →